Immunovant stock falls 8% amid Graves’ disease program update (NASDAQ:IMVT)09/10/2024 [ad_1] designer491/iStock by way of Getty Images Immunovant (NASDAQ:IMVT) stock fell 8% Monday after it reported knowledge from a Phase 2a research of batoclimab within the…
